Schmitz-Peiffer Related News
New drug a potential treatment for Type 2 diabetes
MEDIA RELEASE:
22 Jul 2010
Garvan scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes. Lysofylline, an anti-inflammatory drug, is currently undergoing clinical trials for other diseases.
Solving a critical part of the insulin puzzle
MEDIA RELEASE:
04 Oct 2007
We are now one step closer to improved treatment of Type 2 diabetes following significant findings made by scientists at the Garvan Institute of Medical Research. The team from Garvan's Diabetes Signalling Unit, led by Associate Professor Trevor Biden and Dr Carsten Schmitz-Peiffer, has identified a very important biological target that will enable them to address one of the major underlying causes of diabetes.
